---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032103"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:19:47.210326+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ZyVersa receives Nasdaq notice for non-compliance with minimum MVPHS of $5M

## Summary
- Nasdaq letter dated Sept 1, 2023 for failure to meet minimum Market Value of Publicly Held Shares of $5M.
- Company has 180 calendar days, until Feb 28, 2024, to regain compliance by closing MVPHS ≥$5M for 10 consecutive business days.
- Failure to regain compliance could lead to delisting; company may consider transfer to Nasdaq Capital Market.
- Common stock continues to trade on Nasdaq Global Market under symbol ZVSA with no immediate effect.

## SEC filing metadata
- accession: 0001493152-23-032103
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223032103/0001493152-23-032103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223032103/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032103
- JSON: https://secwatch.observer/filing/0001493152-23-032103.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032103.txt

## Key facts
- Listing & Compliance Notices
  ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(1)(C), 5810(c)(3)(D)
  source text: September 1, 2023, ZyVersa Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the Company is not in compliance with the requirement of a minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(1)(C). Nasdaq calculates MVPHS by subtracting from the total shares of common stock outstanding any shares held by officers, directors or any person who benefic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223032103/0001493152-23-032103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.